---
title: 'Key Prognostic Factors Create a Composite Risk Score to Stratify Patients
  into High- and Low-Treatment Benefit Groups: A Multicenter, Retrospective Data Analysis
  of 84 Metastatic Colorectal Cancer Patients Treated with Regorafenib as Part of
  the CORRECT and CONSIGN Trials'
date: '2023-08-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37607525/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230823181405&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: The presented composite risk score stratifies patients
  into two prognostic subgroups characterized by standard laboratory values. Patients
  with signs of systemic inflammation characterized by elevated NLR, AP, and CRP have
  a high composite risk score and a significant shorter overall survival. Although
  this score needs to be prospectively validated in larger cohorts, it may be used
  to stratify patients suitable for further-line treatment ...'
disable_comments: true
---
CONCLUSIONS: The presented composite risk score stratifies patients into two prognostic subgroups characterized by standard laboratory values. Patients with signs of systemic inflammation characterized by elevated NLR, AP, and CRP have a high composite risk score and a significant shorter overall survival. Although this score needs to be prospectively validated in larger cohorts, it may be used to stratify patients suitable for further-line treatment ...